Table 1 Characteristics of 103 patients started on PCSK9 inhibitor therapy
|  |  |  |  | Mean ± SD, Median At Entry | |||||
|---|---|---|---|---|---|---|---|---|---|
Mean ± SD, Median | Race/ Gender | Statin intolerant | Praluent (P)/Repatha (R) | Age | BMI | TC | TG | HDLC | LDLC |
All, N = 103 | B 15 (15 %); W 88 F 58 (56 %); M 45 | 73 (71 %) | 64 (62 %) P 39 (38 %) R | 62 ± 10, 63 | 29.6 ± 5.4, 29 | 250 ± 59, 246 | 165 ± 86, 142 | 53 ± 16, 53 | 166 ± 55, 149 |
CVD, n = 61 1st CVD age 54 ± 11, 55 | B8 (13 %); W 53 F 29 (48 %); M 32 | 39 (64 %) | 42 (69 %) P 19 (31 %) R | 65 ± 9, 66 | 30.1 ± 5.1, 29.7 | 234 ± 56, 225 | 168 ± 98, 139 | 52 ± 18, 50 | 150 ± 51, 139 |
HeFH+ CVD, n = 28 1st CVD age 53 ± 12, 55 | B 7 (25 %); W 21 F 19 (68 %); M 9 | 16 (57 %) | 18 (64 %) P 10 (36 %) R | 59 ± 11, 61 | 31.5 ± 5.4, 30.9 | 269 ± 59, 268 | 159 ± 77, 133 | 56 ± 19, 54 | 181 ± 55, 191 |
CVD, no HeFH, n = 33 1st CVD age 55 ± 11, 56 | B 1 (3 %); W 32 F 10 (30 %); M23 | 23 (70 %) | 24 (73 %) P 9 (27 %) R | 65 ± 10, 66 | 28.8 ± 4.6, 28.7 | 205 ± 33, 211 | 177 ± 113, 147 | 49 ± 17, 47 | 123 ± 26, 132 |
No CVD, n = 42 | B 7 (17 %), W 35 F 29 (69 %); M 13 | 34 (81 %) | 22 (52 %) P 20 (48 %) R | 59 ± 11, 59 | 29.1 ± 5.9, 28.6 | 272 ± 56, 256 | 159 ± 66, 155 | 55 ± 14, 56 | 187 ± 53, 181 |
HeFH, no CVD, n = 33 | B 4 (12 %), W 29 F 22 (67 %); M 11 | 26 (79 %) | 18 (55 %) P 15 (45 %) R | 56 ± 11, 57 | 28.8 ± 5.6, 28.5 | 284 ± 58, 270 | 165 ± 70, 156 | 55 ± 14, 56 | 198 ± 54, 189 |
No HeFH & no CVD, n = 9 | B 3 (33 %); W6 F 7 (78 %); M 2 | 8 (89 %) | 4 (44 %) P 5 (56 %) R | 63 ± 13, 64 | 29.9 ± 7.0, 29.0 | 231 ± 15, 233 | 137 ± 48, 154 | 56 ± 13, 55 | 148 ± 17, 149 |